45LOW

IDT

IDT AUST FPO [IDT]
IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States. The company offers microbiological and analytical testing, clinical packaging, and pharmacy services. It also provides medicinal cannabis and psychedelics; oral finished doses; and aseptic fill and finish solutions for liquid and lyophilised forms. In addition, the company offers mRNA and antibody drug conjugates. Further, the company provides contract manufacturing services. IDT Australia Limited was founded in 1975 and is headquartered in Boronia, Australia.
Healthcare · ASX Small Cap
$0.0440 -2.2%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical53
Catalyst50
Sentiment50
Fundamental66
Momentum27
Risk Gate41
Get alerts when IDT's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track IDT — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD momentum is picking up steam
  • Volume surging at 2.6x normal while price falls — heavy selling pressure
  • Cash positive / operating cashflow positive
  • Low P/S ratio (1.0x)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (4% of range)
  • Micro-cap ($5-20M) - high risk
  • CANSLIM I: Institutional ownership (18%)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 52% over the past year
  • Altman Z-Score grey zone (1.84, low-confidence approx)
  • Low-priced stock risk ($0.044)
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Revenue declining (-7%)
  • Deeply negative margins (-32%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • The bigger volume days are the down days — volume-weighted momentum is negative (-0.66%/day)
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about IDT
"What's driving IDT's score?" "How does IDT compare to peers?" "Key risks for IDT?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Change of Director's Interest Notice - MS
NONE 1HFY26 Results Presentation
NONE 1HFY26 Results

Recent ASX Announcements

2026-02-23 Change of Director's Interest Notice - MS
2026-02-17 1HFY26 Results Presentation PRICE SENSITIVE
2026-02-17 1HFY26 Results PRICE SENSITIVE
2026-02-17 1HFY26 Appendix 4D and Half Year Report PRICE SENSITIVE

Key Metrics

$18.8M
Market Cap
92K
Avg Volume
2.6x
Vol Ratio
$0.04 — $0.12
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-26.1%
ROE
-32.3%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 72%
LLeader vs LaggardlaggardRS: -3
IInstitutional SponsorshippassInst: 18%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #72 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:IDT vs ATXIDT vs PNVIDT vs IMM
Scout Pro — Deeper Analysis for IDT
Try Pro free for 30 days
Share this analysis

Track IDT and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required